NIAID has a new funding opportunity “Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed)”. For any questions, applicants are strongly encouraged to contact [...]
Keeping the Promise -a New report from a group of 12 product development partnerships (PDPs) including TBVI
The Institute of Health and Development of the Cheikh Anta Diop University (ISED-UCAD), Dakar, Senegal, is offering scholarships for the 2022-2023 academic year, start in February 2022, for a [...]
27 January IAS (International AIDS Society) and TBVI are co-chairing a virtual satellite ‘HIV & TB: An R&D tale of two vaccines’. This virtual satellite will examine lessons learned from [...]
To fight tuberculosis, better vaccination strategies are needed. Two recent publications demonstrate the positive effects of alternative mucosal routes of administration on the ensuing innate and [...]
The Amsterdam Institute for Global Health and Development (aighd) is posting the Global Roadmap for R&D for TB vaccines (roadmap) that they have been developing with key stakeholders ( [...]
Nature published the outcome of a study that demonstrated that a single intradermal vaccination with MTBVAC given to adult rhesus macaques was well tolerated and conferred a significant [...]
Runderweg 6
8219 PK Lelystad
The Netherlands
Email: info@tbvi.eu
Phone: 0031 (0)6 1099 5196
